Seroprevalence of anti-SARS-CoV-2 IgG antibodies among truck drivers and assistants in Kenya

Introduction

Serosurveillance for antibodies to the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) can be used to estimate the cumulative incidence of SARS-CoV-2 infection. This is of particular interest among frontline workers, such as truck drivers and their assistants (TDA), who are exempted from coronavirus disease 2019 (COVID-19) restrictions such as curfews and lockdowns.

Shortly after the first locally detected SARS-CoV-2 infection in March 2020, the Government of Kenya instituted containment measures, including travel restrictions[1]. Freight transportation was excluded from travel restrictions as TDA were deemed essential workers [2]. In May 2020 the Kenya Ministry of Health implemented mandatory bimonthly SARS-CoV-2 nucleic acid testing (NAT) for TDA, in line with East African Community (EAC) guidelines[3, 4]. Though NAT data can be used to estimate the cumulative incidence of SARS-CoV-2 infection[5], accurate estimates are dependent on the availability of reliable model parameter values.

There are currently no estimates of SARS-CoV-2 antibody seroprevalence among TDA globally. Due to the nature of their work, TDA interact with a wide variety of social and professional contacts over a large geographical area, putting them at increased risk of SARS-CoV-2 infection. We undertook a serosurvey to estimate the prevalence of SARS-CoV-2 antibodies among TDA in Kenya.

Methods

Results

The serosurvey was conducted in Magarini between September 30 and October 23, 2020 and in Busia County on October 13-15, 2020. In total, 830 TDA (Busia OSBP n= 365; Magarini n= 101; Malaba OSBP n= 364) provided a blood sample, representing 52.4% of TDA approached (Supplementary Figure 3). Of the 830 samples, 91.1% were collected between October 13-15 (Supplementary Figure 4). The median age of sampled TDA was 40 years (IQR 34-48 years) and 668 (80.5%) were Kenyan. Only 3 (0.4%) of the TDA were female (Table 1). Among Kenyan TDA, reported county of residence included 31 of the country’s 47 counties. The most common counties of residence were Mombasa, Uasin Gishu and Nakuru (Supplementary Table 1). Driver vs assistant status was not recorded but, on the basis of truck driver licensure age requirements, at least 53 (6.4%) were assistants.

Of 785 TDA with available NAT results, 58 (7.4%) were positive for SARS-CoV-2 (Table 1) with NAT positivity being significantly higher in Magarini (25 of 93; 26.9%) compared to Busia OSBP (15 of 348; 4.3%) and Malaba OSBP (18 of 344; 5.2%; p <0.001; Supplementary Table 2). None of the 830 TDA reported current or previous symptoms of illness. Only one individual had a temperature of 37.5°C or higher (Supplementary Table 2) and the NAT result was negative in that one case.

Crude overall anti-SARS-CoV-2 IgG seroprevalence among sampled TDA was 39.6% (95% confidence interval 36.3-43.1). After adjustment for assay sensitivity and specificity it was 42.3% (95% credible interval 38.4-46.3). Seroprevalence was highest in those <30 years of age and lowest among those aged ≥50 years. All three female TDA were seropositive for anti-SARS-CoV-2 IgG. Seroprevalence was 39.6% (35.0-43.9) among TDA negative for SARS-CoV-2 by NAT and 59.0% (46.0-72.1) among those with a positive SARS-CoV-2 NAT result. Seroprevalence among Kenyan TDA was comparable to that of other nationalities. By site, seroprevalence was highest at Busia OSBP and lowest at Malaba OSBP. Crude heterogeneity tests and uncertainty intervals for antibody test-adjusted estimates suggested no significant association between seroprevalence and age and significant differences in seroprevalence by site (Table 1 and Supplementary Table 3). Stratum-specific adjusted seroprevalence estimates were generally higher than crude estimates (Table 1).

Discussion

We estimate that approximately 4 in 10 TDA in Kenya had been infected with SARS-CoV-2 by late October 2020, as the country experienced the initial stages of a second pandemic wave [10]. This study is notable for being the first to report SARS-CoV-2 seroprevalence among TDA.

Anti-SARS-CoV-2 IgG seroprevalence among TDA was more than 4-fold higher compared to average seroprevalence among Kenyan blood donors by September 2020[11] and 2-fold higher compared to average seroprevalence in HCW across five Kenyan health facilities by October 2020 [12]. As such, the findings suggest exposure to SARS-CoV-2 among TDA in Kenya was higher than in the general population and among other frontline workers.

Some studies found seroprevalence of SARS-CoV-2 antibodies among HCW similar to that among TDA in Kenya: 45% in London[13]; 44% in Indiana[14]; and 45% in Ibadan, Nigeria[15]. However, meta-analyses of studies globally estimated SARS-CoV-2 antibody prevalence among HCWs at 7% by July 2020 [16] and 9% by August 2020[17]. Taken together, these data suggest exposure to SARS-CoV-2 among TDA was higher than among HCWs in most settings.

To date, few studies have assessed SARS-CoV-2 antibody prevalence in non-healthcare frontline workers. Seroprevalence was 38% seroprevalence among male migrant supermarket workers in Kuwait in May to June 2020 (during a peak in daily COVID-19 cases)[10, 18]. Elsewhere, however, seroprevalence among non-HCWs has been much lower. SARS-CoV-2 antibody seroprevalence was 1% in Croatia, just prior to easing of nationwide COVID-19 restrictions in late April 2020[19]; 9-11% in France following the initial pandemic wave[20]; 20% in Chicago, Illinois, US during the summer of 2020 following easing of COVID-19 restrictions[21]; and 19-22% in Iran following the initial pandemic wave[22].

This study provides some insights into SARS-CoV-2 epidemiology among TDA. None of the TDA with a positive NAT result reported symptoms within two weeks of testing and no instances of pyrexia were identified among them. This suggests a preponderance of asymptomatic COVID-19 among TDA. Although data on symptoms among TDA may have been subject to reporting bias, 93% of SARS-CoV-2 infections confirmed in Kenya by October 23, 2020 were asymptomatic[23]. The similarity in anti-SARS-CoV-2 antibody seropositivity among Kenyan and non-Kenyan TDA indicates predominantly occupation-related exposure to SARS-CoV-2. That seroprevalence differed by sampling site suggests some heterogeneity in risk of exposure.

Despite sampling at three different sites, we cannot be sure that the sample included are representative of all TDA in Kenya, or even those transiting through these sites. Participation in the serosurvey was voluntary, only half of those approached agreed to be sampled, and sociodemographic data for the target population are not available, limiting our ability to assess recruitment bias. However, data on county of residence for Kenyan TDA indicates representation from most counties. Seroprevalence estimates did not account for clustering by site or by driver-assistant pairs. The use of antibodies to estimate cumulative incidence of SARS-CoV-2 infection assumes universal seroconversion, minimal mortality and antibody persistence. If these assumptions are incorrect – for example, there is evidence suggestive of antibody waning[24–26] – the cumulative incidence of infection would be underestimated. To minimize bias due to assay sensitivity and specificity, adjusted seroprevalence estimates were calculated.

These findings indicate substantial occupational risk for SARS-CoV-2 infection in TDA, despite prevention measures. In turn, infected TDA can transmit SARS-CoV-2 over a large geographical area. Although this study did not assess the contribution of TDA to SARS-CoV-2 transmission, TDA have been previously associated with spatial spread of emerging infections[27–30]. As TDA will continue to play an essential role during the COVID-19 pandemic, heightened promotion of existing COVID-19 prevention measures is needed, as is consideration of prioritization of TDA for COVID-19 vaccines with transmission-blocking potential. Nevertheless, supply chains are essential to sustain daily life and for the COVID-19 response. It remains a challenge how to best balance the essential role of TDA with pandemic control.

Funding

This project was funded by the Wellcome Trust (grants 220991/Z/20/Z and 203077/Z/16/Z), the Bill and Melinda Gates Foundation (INV-017547), and the Foreign Commonwealth and Development Office (FCDO) through the East Africa Research Fund (EARF/ITT/039) and is part of an integrated programme of SARS-CoV-2 serosurveillance in Kenya led by KEMRI-Wellcome Trust Research Programme. The views expressed in this publication are those of the authors and not necessarily those of the funding agencies.

Potential conflicts of interest

RA, MM, KK and PA are from the Ministry of Health, Government of Kenya. All other authors declare no competing interests.